Cannabis and Hemp Industry Investment News
Hill Street will gain exclusive global rights to Lexaria’s DehydraTECH technology for use in non-pharmaceutical products that contain over 0.3% THC, w...
DehydraTECH works by making active ingredients like CBD more easily absorbed into the bloodstream when ingested orally Lexaria Bioscience Corp (OTC:LX...
As of October 21, Lexaria has already processed around 4.2 million servings and has confirmed purchase orders to process a total of over 8 million ser...
The patent includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs and vitamins to treat a range o...
The drug delivery specialist said Altria now has non-exclusive license rights to use its DehydraTECH technology for both the US and worldwide markets ...
Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval...
Now that the company has the blessing of its ethics board, it will begin the process of filing for approval from federal regulators Lexaria also annou...
Lexaria also has received verbal requests from existing licensees to prepare its facilities to produce at least 56 million servings during the calenda...
The new patent protects the use of Lexaria's DehydraTECH technology together with cannabinoids, nicotine and nonsteroidal anti-inflammatory drugs Lexa...
Boldt Runners' Cannadips CBD is the leading CBD oral pouch brand in America, and Lexaria's fast-acting absorption technology is inside every tin Boldt...
What are you searching for? viewLexaria Bioscience Corp. Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactiv...
Lexaria said the agreement does not contemplate the development of oral nicotine consumer products in North America Lexaria Bioscience Corp () () anno...
The study will evaluate blood pressure reduction in 24 pre- or mild hypertension patients, who will receive a 300 milligram dose of CBD with or withou...
The group believes a successful uplisting should provide significant benefits to its shareholders that include increased liquidity, a much larger audi...
What are you searching for? viewLexaria Bioscience Corp. Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactiv...
The oral nicotine formulation demonstrated “acceptable” chemical and microbiological stability and saw no issues with throat irritation in oral pouch ...
The application is being made following the National Institute of Allergy and Infectious Diseases (NIAID) Funding Opportunity Announcement (FOA) RFA-A...
Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredientsCannabis is the c...
Proceeds from the offering will also be used to fund the group's application process to list on a senior US exchange The Canadian company raised a tot...
A portion of the funds will be used for the group's human pilot study on DehydraTECH's ability to boost the oral bioavailability of antiviral drugs Le...
